CD8A and Middle East respiratory syndrome: Survivors of the 2002–2003 SARS outbreak still maintain CD4+ and CD8+ T cell populations reactive to the SARS-CoV-1 nucleocapsid protein (10), and evidence of sustained T cell memory has also been found for Middle East respiratory syndrome (MERS) (11).